#fgfr3

[halloigor]

FGFR3, dosis y seguimiento: claves para entender Erdafitinib

Las pruebas moleculares tienen un papel cada vez más importante en el tratamiento del carcinoma urotelial avanzado. Una de las alteraciones que puede analizarse afecta al gen FGFR3, relacionado con señales que regulan el crecimiento y la supervivencia celular.

Erdafitinib es una terapia dirigida que actúa sobre la vía FGFR. Sin embargo, no está indicado para todos los pacientes con carcinoma urotelial: antes de considerarlo, debe confirmarse una alteración susceptible mediante una prueba molecular validada.

El medicamento se presenta en comprimidos de distintas concentraciones, entre ellas 3 mg y 4 mg. La concentración de cada comprimido no equivale necesariamente a la dosis diaria total, ya que la pauta y los posibles ajustes deben ser definidos por el oncólogo.

Durante el tratamiento pueden ser necesarios controles de fosfato en sangre y evaluaciones oftalmológicas periódicas. Cualquier cambio visual debe comunicarse al equipo médico.

Puede consultarse más información sobre las presentaciones de Erdafitinib y su disponibilidad para pacientes de Latinoamérica.

Contenido exclusivamente informativo. Erdafitinib es un medicamento de prescripción y debe utilizarse bajo supervisión médica.

[freehealthteacher]

New insights into the genomic landscape of meningiomas identified FGFR3 in a subset of patients with favorable prognoses

New insights into the genomic landscape of meningiomas identified FGFR3 in a subset of patients with favorable prognoses

[ad_1]

IMAGE: Figure 1: Characteristics of the meningioma’s investigated in the study. (A) Tumor grade according to the most recent WHO classification. (B) Location of the skull based tumors. (C) Schematic demonstrating… view more 

Credit: Malak Abedalthagafi, email: [email protected]

The identification of oncogenic mutations has provided further insights into the tumorigenesis of…

View On WordPress

[bpod-bpod]

Out of Control

This strange-looking landscape is a close-up photo of a person's skin, studded with small growths known as epidermal naevi. They're caused by normal skin cells growing out of control, and turn up in around one in every 1,000 individuals. And although the growths are harmless, their appearance can be troublesome – surgical removal is a common option, but they tend to come back again. Faults in a gene called FGFR3 have been found in around a third of people with certain types of epidermal naevi, but for everyone else the genetic faults at work are unknown. Normally, FGFR3 sends signals to cells telling them to divide and grow exactly where they're needed, and it's tightly controlled. But within epidermal naevi, the faulty version of FGFR3 is overactive. It's continually driving the skin cells to grow out of control so that they form these characteristic lumps and bumps.

Written by Kat Arney

Image by Hannah Causer

This image is included in the International Images for Science 2015 exhibition, organised by the Royal Photographic Society and supported by Siemens as part of the Curiosity Project.

Copyright held by the photographer

You can also follow BPoD on Twitter and Facebook